Evidence Summary
Evidence Level: Moderate
Mechanism: Enrollment: Actual, Sponsor Type: Other, Unknown / General
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Leukotriene receptor antagonist used as add-on in MCAS and sometimes respiratory phenotypes in long COVID. 10mg daily. Supported by observational MCAS data and urticaria RCTs. Low risk; consider for MCAS-overlap with incomplete antihistamine response.